WO2003025166A1 - Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic - Google Patents
Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic Download PDFInfo
- Publication number
- WO2003025166A1 WO2003025166A1 PCT/FR2001/002872 FR0102872W WO03025166A1 WO 2003025166 A1 WO2003025166 A1 WO 2003025166A1 FR 0102872 W FR0102872 W FR 0102872W WO 03025166 A1 WO03025166 A1 WO 03025166A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mutated
- peptide
- sequence
- mutation
- sequences
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 102
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 34
- 238000002255 vaccination Methods 0.000 title claims abstract description 16
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 title claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 15
- 230000035772 mutation Effects 0.000 claims abstract description 115
- 150000001413 amino acids Chemical class 0.000 claims abstract description 84
- 238000011282 treatment Methods 0.000 claims abstract description 44
- 229960005486 vaccine Drugs 0.000 claims abstract description 37
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 230000004044 response Effects 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 12
- 230000028993 immune response Effects 0.000 claims abstract description 11
- 230000002458 infectious effect Effects 0.000 claims abstract description 10
- 230000007170 pathology Effects 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 7
- 230000002924 anti-infective effect Effects 0.000 claims abstract description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 229910052698 phosphorus Inorganic materials 0.000 claims description 18
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 14
- 229910052700 potassium Inorganic materials 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 108010028921 Lipopeptides Proteins 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108091061960 Naked DNA Proteins 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000002353 niosome Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 abstract description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 229940127073 nucleoside analogue Drugs 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000001173 tumoral effect Effects 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 22
- 102100034349 Integrase Human genes 0.000 description 19
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000000798 anti-retroviral effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000005185 salting out Methods 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960001627 lamivudine Drugs 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 229940124821 NNRTIs Drugs 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101150104269 RT gene Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-M sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Definitions
- Therapeutic vaccination methods mutated HIV reverse transcriptase peptides and their use for vaccination and diagnostic purposes
- the subject of the present invention is a treatment of infectious and tumor pathologies comprising a phase of treatment by anti-infectious and / or anti-tumor chemotherapy inducing resistance mutations and a phase of therapeutic vaccination directed against these resistance mutations and to the agents used. as part of this processing.
- a more particular subject of the present invention is peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence and comprising at least one mutation relative to the wild-type sequence of this enzyme, mutation induced in response to treatments with nucleoside or non-nucleoside analogs of HIV reverse transcriptase.
- the present invention also relates to a pharmaceutical composition or vaccine based on these peptides, in order to induce a specific immune response of these mutated sequences and to reinforce or prolong the effectiveness of the treatments with nucleoside or non-nucleoside analogues of the HIV reverse transcriptase. .
- the present invention also relates to epitopes derived from these peptide sequences in order to evaluate the specific immune response following the injection of a vaccine.
- cytotoxic T lymphocytes are responsible for controlling the initial peak of viremia, low-noise viral replication during the asymptomatic phase of the disease, and the elimination of most viral variants .
- the recognition of an infectious agent as a foreign supposes that the immune system recognizes certain specific foreign structures, the antigens, constituting the non-self, distinguishing them from the structures which belong to it, constituting the self.
- the immune response actors involve:
- lymphocytes which are the effector cells of the immune reaction. They include B and T lymphocytes subdivided into two subpopulations: CD4 + helper T cells (Th), coordinators of specific immune responses, and CD8 + cytotoxic T lymphocytes (CTLs). These CTLs are capable of recognizing and killing cells infected with viruses, in particular, before the virus buds on the surface of the cell and is released into the extracellular medium.
- CTLs cytotoxic T lymphocytes
- These CTLs are capable of recognizing and killing cells infected with viruses, in particular, before the virus buds on the surface of the cell and is released into the extracellular medium.
- the antigen presenting cells which capture the antigens, condition them and present them in immunogenic form to the T lymphocytes.
- MHC molecules major histocompatibility complex which are expressed on the surface of cells and participate in the presentation of the antigen to lymphocytes.
- MHC is called HLA (human leukocyte antigen).
- class I molecules which are present on the surface of all nucleated cells in the body
- class II molecules which are only expressed on the surface of cells presenting antigens.
- Antigenic peptides of 8 to 10 amino acids bind in a niche of MHC class I molecules
- peptides of 14-15 amino acids bind to MHC class I
- Their binding is determined by the interaction forces established between the amino acids (essentially in the two terminal parts) of the antigenic peptide and those of the walls of the niche of HLA molecules.
- HLA class I alleles More than 200 HLA class I alleles have now been defined within the three families of HLA class IA genes, B and C. Each HLA class I allele is significantly different in terms of the peptide niche, so the peptides that can s 'fix it are also different. There is therefore a strict specificity in the interaction between peptide and HLA class I molecule. This specificity explains why even a minor change in the sequence of the peptide presented as target may be sufficient to make this peptide incapable of binding to the HLA molecule class I. * receptors for the antigen which are fixed in the membrane of T lymphocytes
- T lymphocyte specifically recognizes an antigen presented on the MHC.
- the receptor for T lymphocytes is called TCR (T Cell Receptor). This receptor must recognize at the same time on the cell surface the antigenic peptide and the MHC molecule. It is said that recognition is restricted by the CMH.
- CD markers (differentiation cluster) which are molecules whose presence on the cell membrane identifies a cell.
- the Th carry the CD4 marker and are also called CD4 + and the CTLs which carry the marker
- CD8 are called CD8 +.
- CD8 + lymphocytes recognize their antigen on MHC class I; CD4 + lymphocytes on MHC class IL
- the presentation of the antigenic sequences by the antigen presenting cells is one of the determining factors of the effectiveness of a vaccine. It can be amplified by certain natural or synthetic compounds, adjuvants, such as lipids (fatty acids, phospholipids, Freund's adjuvant), anionic copolymers, CpG units ... Other molecules such as cytokines (interleukins , interferons, TNF (tumor necrosis factors), TGF (transforming growth factors %) and chemokines are involved in the regulation of maturation, activation, proliferation and differentiation of cells of the immune system, and play a major role in the molecule of vaccine efficacy.
- adjuvants such as lipids (fatty acids, phospholipids, Freund's adjuvant), anionic copolymers, CpG units ...
- Other molecules such as cytokines (interleukins , interferons, TNF (tumor necrosis factors), TGF (transforming growth factors %) and chemokines are involved in the
- HIV infection is an infection of the immune system in the sense that this virus electively infects CD4 + lymphocytes and antigen-presenting cells and gradually destroys the immune system, usually over 10 years.
- the intensity and diversity of these CTL responses to HIV could be correlated with the control of viral replication, suggesting the crucial role played by these CTLs in these immune defenses.
- CTL target HIV peptide sequences have been defined for the majority of HIV proteins. These targets differ depending on the individual, depending on the HLA class I molecules expressed on the surface of the cells of a given individual.
- the escape of the virus from the control exerted by the immune system is the main cause of the ineffectiveness of these responses.
- Viral variation in CTL epitopes may play a key role in the immune system's failure to contain the virus.
- a single mutation in a defined epitope recognized by a CTL may indeed be sufficient to suppress CTL recognition, or to block the binding of the peptide to the class I molecule, or by altering residues essential for interactions with the TCR.
- the sequence of the HIV Reverse Transcriptase enzyme being highly conserved between the different virus subtypes, it is a prime target for CTL-type immune responses: 80% of the patients tested exhibit a CTL response directed against reverse transcriptase corresponding to HIV-1.
- HIV vaccines include recombinant VLH proteins, synthetic peptides, recombinant viral or bacterial vectors, naked DNA vaccines. More than 60 phase I clinical trials on thirty candidate specific type B vaccines for HIV, which is the most common subtype in the United States and Europe, have been carried out or are underway. Most of these trials have focused on the HIV envelope protein. However, the recombinant proteins tested rarely induce CD8 + CTLs which recognize and kill cells infected with HIV. In addition, type I HIV isolates exhibit a degree of intense genetic diversity in the viral envelope that can affect aspects of the life cycle such as infectivity, transmissibility or immunogenicity.
- AIDS treatments use molecules capable of blocking one or more stages of the virus cycle without altering the proper functioning of the host cells.
- the other structural proteins (the viral capsid and reverse transcriptase, in particular) as well as the regulatory proteins, which are more conserved than the viral envelope, are today the preferred targets of preventive vaccination strategies.
- RT Reverse transcriptase
- NRTI Non-hydrolyzable nucleoside analogs
- AZT zidovudine
- DDI didanosine
- DDC zalcitabine
- 3TC lamivudine
- ABC abacavir
- D4T stavudine
- NRTI non-nucleoside inhibitors of the enzyme
- HIV protease is the other main target of anti-retroviral treatments that use enzyme inhibitors such as Ritonavir,
- NNRTI within one to twelve months of processing.
- the accumulation of these mutations over time in patients treated with these drugs leads to the selection of multidrug-resistant viruses and leads to therapeutic failures.
- HIV treated with at least one reverse transcriptase inhibitor in Western countries 50% of them maintain a detectable viremia and are considered to be in therapeutic failure. This is associated with the existence of at least one resistance mutation to these inhibitors and results in an increase in the viral load and a decrease in CD4 + T lymphocytes.
- 10% of patients recently infected, but not yet treated are infected with new viral strains carrying mutations in resistance to antiretroviral treatment. Numerous studies have shown that subsequent antiviral therapies with molecules of the same class then have less effectiveness on these resistant viruses.
- An alternative therapeutic strategy is now proposed in order to limit the toxicity and the cost of these long-term treatments.
- the aim is to stimulate the immune responses to HIV in treated patients by combining these treatments with anti-HIV immunization by the available vaccine candidates in order to discontinue the treatments in the long term.
- the Applicant has discovered a treatment for infectious and tumor pathologies comprising a phase of treatment with anti-infectious and / or anti-tumor chemotherapy inducing resistance mutations and a phase of therapeutic vaccination directed against these resistance mutations.
- This immune response can therefore take place during these treatments, but seems incapable of ensuring the elimination of specific variants on its own. Amplification of the immunity directed against these mutations will make it possible to control the emergence of these variants of HIV and to maintain a lasting viral suppression under these treatments.
- the administration of vaccines containing these mutated reverse transcriptase viral sequences, before or during the administration of NRTI or NNRTI treatments should make it possible to prevent, delay or reduce the appearance of mutated viruses capable of resisting these treatments.
- This new type of therapeutic immunization thus aims to strengthen or prolong the effectiveness of antiretroviral treatments with NRTIs and / or NNRTIs. This can be secondarily applied to other mutations induced by other classes of antiretrovirals and can also be used in preventive vaccination.
- the invention therefore consists in a treatment of infectious and / or tumor pathologies.
- the invention also consists of the treatment agents used in the context of this treatment.
- the subject of the invention is also the preparation of immunogens containing the mutations of resistance to NRTI and / or NNRTI.
- the invention consists in the preparation of immunogens containing the resistance mutations to one or more NNRTIs used alone or in conjunction with one or more NRTIs.
- the subject of the invention is also the peptides which are elements of immunogens.
- Another subject of the invention is a pharmaceutical composition characterized in that it comprises at least one peptide as defined, dispersed in pharmaceutically acceptable excipients, this composition being used as a vaccine.
- Another object of the invention is the determination of epitopes recognized by the
- the method for treating infectious and / or tumor pathologies comprises a phase of treatment by anti-infectious and / or antitumour chemotherapy inducing resistance mutations and a phase of therapeutic vaccination directed against these resistance mutations.
- the vaccination phase follows the chemotherapy treatment phase.
- the present invention also relates to an agent for treating infectious and / or tumor pathologies which comprises at least two components:
- the first component comprising a medicament intended for the treatment of infectious and or anti-tumor pathologies inducing resistance mutations
- the second component comprising a vaccine directed against these resistance mutations, the two components being intended for simultaneous, separate or sequential use over time.
- the present invention also relates to peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence comprising at least one mutation by substitution and / or by single or multiple insertion with respect to established reverse transcriptase sequences, in the absence of any treatment, mutation observed following treatment with NRTI and / or NNRTI, the peptides being characterized by the fact that they are capable of inducing a response mediated by T lymphocytes specific for this mutated sequence of HIV reverse transcriptase, with the exception of peptides of sequence Z r YVDDZ 2 , Z r YIDDZ 2 and Z r
- YLDD-Z2 with Z x and Z 2 being at least any amino acid, these peptides having been observed following treatment with lamivudine alone (NRTI).
- the subject of the invention is preferably peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence comprising at least one mutation by substitution and / or by single or multiple insertion with respect to the established sequences of the reverse transcriptase, in the absence of any treatment, mutation observed following treatment with NNRTI alone or following treatment combining NNRTI and NRTI, the peptides being characterized by the fact that they are capable of induce a response mediated by T lymphocytes specific for this mutated sequence of VLH reverse transcriptase.
- the peptides according to the invention contain from 15 to 50 amino acids.
- sequences of the peptides according to the invention can be preceded or followed by neutral amino acids which can dissolve or stabilize the peptides.
- the peptides according to the invention are characterized by the sequences or parts of sequence comprising at least one of the following Mp mutation with Xn being an amino acid corresponding to that described in the Los Alamos database at the same position of the peptide sequence of HIV-1 reverse transcriptase, and n being the position of an amino acid described in the Los Alamos database in the sequence of HIV-1 reverse transcriptase, and with Mp being a mutated amino acid and p being the number of the mutation observed.
- Ml (aa 6) can be mutated into K, G or S
- M2 (aa 39) can be X39 or be mutated into A, K, N, P, M or S;
- M3 (aa 41) can be X41 or be mutated to L; at least one of M2 and M3 representing an amino acid carrying a mutation.
- M2 (aa 39) can be mutated to A, K, N, P, M or S;
- M3 (aa 41) can be X41 or be mutated to L;
- Ml (aa 6) can be X6 or be mutated into K, G or S;
- M2 (aa 39) can be X39 or be mutated to A, K, N, P, M or S;
- M3 (aa 41) can be X41 or be mutated to L; at least one of Ml, M2 and M3 representing an amino acid carrying a mutation.
- Ml (aa 6) can be X6 or be mutated into K, G or S;
- M2 (aa 39) can be X39 or be mutated to A, K, N, P, M or S;
- M3 (aa 41) can be X41 or be mutated to L; with Ml or M2 representing an amino acid carrying a mutation.
- M4 (aa 62) can be X62 or be mutated into V;
- M5 (aa 65) can be X65 or be mutated to R;
- M6 (aa 67) can be X67 or be mutated to N or G;
- M7 (aa 68) can be X68 or be mutated to G or N;
- M8 (aa 69) can be X69 or be mutated to D, N, S, A, or combined with multiple inserts like SG, SX, SSA, SSG, SSS, SEA, STS, ASG, SXX, or XXX;
- M9 (aa 70) can be X70 or be mutated to R, N, E or S; M10 (aa 74) can be X74 or be mutated into V or I; Ml 1 (aa 75) can be X75 or be mutated to M, I, L or T;
- M12 (aa 77) can be X77 or be mutated to L; at least one of M4 to Ml 2 representing an amino acid carrying a mutation.
- M4 (aa 62) can be X62 or be mutated to V
- M5 (aa 65) can be X65 or be mutated to R
- M6 (aa 67) can be X67 or be mutated to N or G;
- M7 (aa 68) can be X68 or be mutated to G or N;
- M8 (aa 69) can be X69 or be mutated to D, N, S, A, or combined with multiple inserts like SG, SX, SSA, SSG, SSS, SEA, STS, ASG, SXX, or XXX;
- M9 (aa 70) can be X70 or be mutated to R, N, E or S;
- M10 (aa 74) can be X74 or be mutated into V or I;
- Mil (aa 75) can be X75 or mutated to M, I, L or T;
- M12 (aa 77) can be X77 or be mutated to L; at least one of M4, M7 or M12 representing an amino acid carrying a mutation.
- M4 (aa 62) can be X62 or be mutated into V;
- M5 (aa 65) can be X65 or be mutated to R;
- M6 (aa 67) can be X67 or be mutated to N or G;
- M7 (aa 68) can be X68 or be mutated to G or N;
- M8 (aa 69) can be X69 or be mutated to D, N, S, A, or combined with multiple inserts like SG, SX, SSA, SSG, SSS, SEA, STS, ASG, SXX, or XXX;
- M9 (aa 70) can be X70 or be mutated to R, N, E or S;
- M10 (aa 74) can be X74 or be mutated into V or I;
- Mil (aa 75) can be X75 or mutated to M, I, L or T;
- M12 (aa 77) can be X77 or be mutated to L;
- M13 (aa 88) can be X88 or be mutated to C;
- M14 (aa 89) can be X89 or be mutated to G;
- M15 (aa 90) can be X90 or be mutated to I;
- M16 (aa 98) can be X98 or be mutated into G or S;
- M17 (aa 100) can be X100 or be mutated to I;
- M18 (aa 101) can be X101 or be mutated to E, Q, R, I or P;
- M19 (aa 103) can be X103 or be mutated to N, Q, R, T or S;
- M20 (aa 106) can be X106 or be mutated to A, I or L;
- M21 (aa 108) can be X108 or be mutated to I;
- M22 (aa 115) can be XI 15 or be mutated to F;
- M23 (aa 116) can be XI 16 or be mutated to Y;
- M24 (aa 119) can be XI 19 or be mutated to S; at least one of M4 to M24 representing an amino acid carrying a mutation.
- M4 (aa 62) can be X62 or be mutated to V;
- M5 (aa 65) can be X65 or be mutated to R;
- M6 (aa 67) can be X67 or be mutated to N or G;
- M7 (aa 68) can be X68 or be mutated to G or N;
- M8 (aa 69) can be X69 or be mutated to D, N, S, A, or combined with multiple inserts like SG, SX, SSA, SSG, SSS, SEA, STS, ASG, SXX, or XXX;
- M9 (aa 70) can be X70 or be mutated to R, N, E or S;
- M10 (aa 74) can be X74 or be mutated into V or I;
- Ml 1 (aa 75) can be X75 or be mutated to M, I, L or T;
- M12 (aa 77) can be X77 or be mutated to L;
- M13 (aa 88) can be X88 or be mutated to C;
- M14 (aa 89) can be X89 or be mutated to G;
- Ml 5 (aa 90) can be X90 or be mutated to I;
- Ml 6 (aa 98) can be X98 or be mutated to G or S;
- M17 (aa 100) can be X100 or be mutated to I;
- M18 (aa 101) can be X101 or be mutated to E, Q, R, I or P;
- M19 (aa 103) can be X103 or be mutated to N, Q, R, T or S;
- M20 (aa 106) can be X106 or be mutated to A, I or L;
- M21 (aa 108) can be X108 or be mutated to I;
- M22 (aa 115) can be XI 15 or be mutated to F;
- M23 (aa 116) can be XI 16 or be mutated to Y;
- M24 (aa 119) can be XI 19 or be mutated to S; at least one of M4, M7, M12 to M21, M23 or M24 representing an amino acid carrying a mutation.
- Sequence F aa 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143
- M25 (aa 138) can be XI 38 or be mutated into A, G, K or Q;
- M26 (aa 139) can be X139 or be mutated to I, M or K;
- M27 (aa 141) can be X141 or be mutated to E;
- M28 (aa 151) can be X151 or be mutated to M;
- M29 (aa 157) can be X157 or be mutated to S; at least one of M25 to M29 representing an amino acid carrying a mutation.
- M25 (aa 138) can be X138 or be mutated to A, G, K or Q;
- M26 (aa 139) can be X139 or be mutated to I, M or K;
- M27 (aa 141) can be X141 or be mutated to E;
- M28 (aa 151) can be X151 or be mutated to M;
- M29 (aa 157) can be X157 or be mutated to S; at least one of M25 to M28 representing an amino acid carrying a mutation.
- M31 (aa 178) can be X178 or be mutated to M, L, or F M32 (aa 179) can be X179 or be mutated to I, L, D or E;
- M33 (aa 181) can be X181 or be mutated to C or I;
- M34 (aa 184) can be X184 or be mutated to V, I or T;
- M35 (aa 188) can be X188 or be mutated into L, C or H;
- M36 (aa 189) can be XI 89 or be mutated to I;
- M37 (aa 190) can be X190 or be mutated to A, S, E, Q or T; at least one of M30 to M37 representing an amino acid carrying a mutation.
- M30 (aa 172) can be X172 or be mutated to K;
- M31 (aa 178) can be X178 or be mutated to M, L, or F
- M32 (aa 179) can be X179 or be mutated to I, L, D or E;
- M33 (aa 181) may be XI 81 or be mutated to C or I;
- M34 (aa 184) can be XI 84 or be mutated to V, I or T;
- M35 (aa 188) can be XI 88 or be mutated into L, C or H;
- M36 (aa 189) can be XI 89 or be mutated to I;
- M37 (aa 190) can be X190 or be mutated to A, S, E, Q or T; at least one of M30, M33, M35 to M37 representing an amino acid carrying a mutation.
- M30 (aa 172) may be X172 or be mutated to K;
- M31 (aa 178) can be X178 or be mutated to M, L, or F;
- M32 (aa 179) can be X179 or be mutated into I, L, D or E;
- M33 (aa 181) can be X181 or be mutated to C or I;
- M34 (aa 184) can be X184 or be mutated to V, I or T; at least one of M30 to M34 representing an amino acid carrying a mutation.
- M30 (aa 172) can be X172 or be mutated to K;
- M31 (aa 178) can be X178 or be mutated to M, L, or F;
- M32 (aa 179) can be X179 or be mutated into I, L, D or E;
- M33 (aa 181) may be XI 81 or be mutated to C or I;
- M34 (aa 184) can be XI 84 or be mutated to V, I or T; at least one of M30; M32 or M33 representing an amino acid carrying a mutation. Sequence I
- M34 (aal84) can be XI 84 in which M35 (aa 188) can be X188 or be mutated in L, C or H; M36 (aa 189) can be XI 89 or be mutated to I;
- M37 (aa 190) can be X190 or be mutated to A, S, E, Q or T; at least one of M34 to M37 representing an amino acid carrying a mutation.
- M34 (aal 84) can be XI 84 in which M35 (aa 188) can be X188 or be mutated into L, C or H;
- M36 (aa 189) can be XI 89 or be mutated to I;
- M37 (aa 190) can be X190 or be mutated to A, S, E, Q or T; at least one of M35 to M37 representing an amino acid carrying a mutation.
- M38 (aa 208) may be X208 or be mutated to Y;
- M39 (aa 210) can be X210 or be mutated to W;
- M40 (aa 211) can be X211 or mutated to K, A, E, N, D, G or Q;
- M41 (aa 214) can be X214 or be mutated into L or F;
- M42 (aa 215) can be X215 or be mutated to Y, F or C;
- M43 (aa 219) can be X219 or be mutated to Q, E N, R, T or W;
- M44 (aa 223) can be X223 or be mutated to Q;
- M45 (aa 225) can be X225 or be mutated to H;
- M46 (aa 227) can be X227 or be mutated to L;
- M47 (aa 228) can be X228 or be mutated to R, H or F;
- M48 (aa 233) can be X233 or be mutated to V or N;
- M49 (aa 234) can be X234 or be mutated into I, H or P;
- M50 (aa 236) can be X236 or be mutated to M, S or L;
- M51 (aa 238) can be X238 or be mutated to T or S;
- M52 (aa 240) can be X240 or be mutated to A, D or I; at least one of M38 to M52 representing an amino acid carrying a mutation.
- M38 (aa 208) can be X208 or be mutated to Y;
- M39 (aa 210) can be X210 or be mutated to W;
- M40 (aa 211) can be X211 or mutated to K, A, E, N, D, G or Q;
- M41 (aa 214) can be X214 or be mutated into L or F;
- M42 (aa 215) can be X215 or be mutated to Y, F or C;
- M43 (aa 219) can be X219 or be mutated to Q, E N, R, T or W;
- M44 (aa 223) can be X223 or be mutated to Q;
- M45 (aa 225) can be X225 or be mutated to H;
- M46 (aa 227) can be X227 or be mutated to L;
- M47 (aa 228) can be X228 or be mutated to R, H or F;
- M48 (aa 233) can be X233 or be mutated to V or N;
- M49 (aa 234) can be X234 or be mutated into I, H or P;
- M50 (aa 236) can be X236 or be mutated to M, S or L;
- M51 (aa 238) can be X238 or be mutated to T or S;
- M52 (aa 240) can be X240 or be mutated to A, D or I; at least one of M38, M40, M44 to M52 representing an amino acid carrying a mutation.
- the peptides according to the invention are characterized by the following sequences or parts of sequence comprising at least one of the following Mp mutations:
- G K 1 S K I in which M2 (aa 39- wt T) can be X39 or be mutated mainly in A, or in K, or N, or P, or M or S;
- M2 (aa 39) can be mutated to A, K, N, P, M or S;
- M3 (aa 41) can be X41 or be mutated to L;
- Ml (aa 6) can be X6 or be mutated into K, G or S;
- M2 (aa 39) can be X39 or be mutated to A, K, N, P, M or S;
- M3 (aa 41) can be X41 or be mutated to L; with Ml or M2 representing an amino acid carrying a mutation.
- M4 (aa 62) can be X62 or be mutated to V
- M5 (aa 65) can be X65 or be mutated to R
- M6 (aa 67) can be X67 or be mutated to N or G
- M7 (aa 68) can be X68 or be mutated to G or N
- M8 (aa 69) can be X69 or be mutated to D, N, S, A, or combined with multiple inserts like SG, SX, SSA, SSG, SSS, SEA, STS, ASG, SXX, or XXX;
- M9 (aa 70) can be X70 or be mutated to R, N, E or S; M10 (aa 74) can be X74 or be mutated into V or I; Ml 1 (aa 75) can be X75 or be mutated to M, I, L or T;
- M12 (aa 77) can be X77 or be mutated to L; at least one of M4, M7 or M12 representing an amino acid carrying a mutation.
- M4 (aa 62) can be X62 or be mutated to V
- M5 (aa 65) can be X65 or be mutated to R
- M6 (aa 67) can be X67 or be mutated to N or G;
- M7 (aa 68) can be X68 or be mutated to G or N;
- M8 (aa 69) can be X69 or be mutated to D, N, S, A, or combined with multiple inserts like SG, SX, SSA, SSG, SSS, SEA, STS, ASG, SXX, or XXX;
- M9 (aa 70) can be X70 or be mutated to R, N, E or S;
- M10 (aa 74) can be X74 or be mutated into V or I;
- Ml 1 (aa 75) can be X75 or be mutated to M, I, L or T;
- M12 (aa 77) can be X77 or be mutated to L; M13 (aa 88) can be X88 or be mutated to C; M14 (aa 89) can be X89 or be mutated to G; Ml 5 (aa 90) can be X90 or be mutated to I; M16 (aa 98) can be X98 or be mutated into G or S; M17 (aa 100) can be X100 or be mutated to I;
- M18 (aa 101) can be X101 or be mutated to E, Q, R, I or P;
- M19 (aa 103) can be X103 or be mutated to N, Q, R, T or S;
- M20 (aa 106) can be X106 or be mutated to A, I or L;
- M21 (aa 108) can be X108 or be mutated to I;
- M22 (aa 115) can be XI 15 or be mutated to F;
- M23 (aa 116) can be XI 16 or be mutated to Y; M24 (aa 119) can be XI 19 or be mutated to S; at least one of M4, M7, M12 to M21, M23 or M24 representing an amino acid carrying a mutation.
- M25 (aa 138) can be XI 38 or be mutated into A, G, K or Q;
- M26 (aa 139) can be X139 or be mutated to I, M or K;
- M27 (aa 141) can be X141 or be mutated to E;
- M28 (aa 151) can be X151 or be mutated to M;
- M29 (aa 157) can be X157 or be mutated to S; at least one of M25 to M28 representing an amino acid carrying a mutation.
- M31 (aa 178- wt ⁇ I) can be X178 or be transferred mainly to M, L or F;
- M33 (aa 181- wt ⁇ Y) can be XI 81 or be mainly transferred to C or to I;
- M34 (aa 184- wt ⁇ M) can be XI 84 or be mainly transferred to V, or to I or
- T; M35 (aa 188- wt ⁇ Y) can be X188 or be mainly transferred to L, or to C or
- M37 (aa 190- wt ⁇ G) can be X190 or be transferred mainly to A, or to S, or
- M30 (aa 172) can be X172 or be mutated to K;
- M31 (aa 178) can be X178 or be mutated to M, L, or F
- M32 (aa 179) can be X179 or be mutated into I, L, D or E;
- M33 (aa 181) can be X181 or be mutated to C or I;
- M34 (aa 184) can be XI 84 or be mutated to V, I or T;
- M35 (aa 188) can be X188 or be mutated into L, C or H;
- M36 (aa 189) can be XI 89 or be mutated to I;
- M37 (aa 190) can be X190 or be mutated to A, S, E, Q or T; at least one of M30, M33, M35 to M37 representing an amino acid carrying a mutation.
- M33 (aa 181-wt ⁇ Y) can be X181 or be mutated mainly in C or in I;
- T at least one of M30 to M34 representing an amino acid carrying a mutation.
- M30 (aa 172) can be X172 or be mutated to K;
- M31 (aa 178) can be X178 or be mutated to M, L, or F;
- M32 (aa 179) can be X179 or be mutated into I, L, D or E; M33 (aa 181) may be XI 81 or be mutated to C or I;
- M34 (aa 184) can be XI 84 or be mutated to V, I or T; at least one of M30; M32 or M33 representing an amino acid carrying a mutation.
- M36 (aa 189- wt ⁇ V) can be XI 89 or be transferred mainly to I M37 (aa 190- wt ⁇ G) can be X190 or be transferred mainly to A, or S, or E, or Q or T; at least one of M34 to M37 representing an amino acid carrying a mutation.
- M34 (aal84) can be XI 84 in which M35 (aa 188) can be X188 or be mutated into L, C or H;
- M36 (aa 189) can be XI 89 or be mutated to I; M37 (aa 190) can be X190 or be mutated to A, S, E, Q or T; at least one of M35 to M37 representing an amino acid carrying a mutation.
- M38 (aa 208- wt ⁇ H) can be X208 or be transferred mainly in
- M40 (aa 211- wt ⁇ R) can be X211 or be mutated mainly in K, or in A, or E, or N, or D, or G or Q;
- M41 (aa 214- wt ⁇ F or L) can be X214 or be transferred mainly to L or
- M42 (aa 215- wt ⁇ T) can be X215 or be mutated mainly in Y, or in F or C;
- M43 (aa 219- wt ⁇ K) can be X219 or be transferred mainly to Q, or to E, or
- M44 (aa 223- wt ⁇ K) can be X223 or be mainly transferred to Q;
- M45 (aa 225- wt ⁇ P) can be X225 or be transferred mainly to H;
- M46 (aa 227- wt ⁇ F) can be X227 or be mainly transferred to L;
- M47 (aa 228- wt ⁇ L) can be X228 or be mutated mainly in R, or in H or F;
- M48 (aa 233- wt ⁇ E) can be X233 or be mainly transferred to V, or in N M49 (aa 234- wt ⁇ L) can be X234 or be mainly transferred to I, or in H or
- M50 (aa 236- wt ⁇ P) can be X236 or be transferred mainly to M, or to S or L;
- M51 (aa 238- wt ⁇ K) can be X238 or be mainly transferred to T or S;
- M52 (aa 240- wt ⁇ T) can be X240 or be transferred mainly to A, or to D or
- M38 (aa 208) can be X208 or be mutated to Y;
- M39 (aa 210) can be X210 or be mutated to W;
- M40 (aa 211) can be X211 or mutated to K, A, E, N, D, G or Q; M41 (aa 214) can be X214 or be mutated into L or F;
- M42 (aa 215) can be X215 or be mutated to Y, F or C;
- M43 (aa 219) can be X219 or be mutated to Q, E N, R, T or W;
- M44 (aa 223) can be X223 or be mutated to Q;
- M45 (aa 225) can be X225 or be mutated to H; M46 (aa 227) can be X227 or be mutated to L;
- M47 (aa 228) can be X228 or be mutated to R, H or F;
- M48 (aa 233) can be X233 or be mutated to V or N;
- M49 (aa 234) can be X234 or be mutated into I, H or P;
- M50 (aa 236) can be X236 or be mutated to M, S or L;
- M51 (aa 238) can be X238 or be mutated to T or S;
- M52 (aa 240) can be X240 or be mutated to A, D or I; at least one of M38, M40, M44 to M52 representing an amino acid carrying a mutation. * K bis sequence:
- the invention also relates to a pharmaceutical composition based on at least one peptide, dispersed in pharmaceutically acceptable excipients, for their use as a vaccine.
- the pharmaceutical composition according to the invention may also comprise, in addition, immunomodulators such as cytokines or chemokines.
- adjuvants such as lipids (fatty acids, phospholipids, incomplete adjuvant of
- At least one peptide according to the invention is included in the composition of a lipopeptide or a lipoprotein.
- a peptide according to the invention is included in the composition of a lipopeptide or a lipoprotein.
- the peptide (s) according to the invention can be coupled to micro or nanoparticles made up of a polysaccharide nucleus and / or covered in particular with a lipid bilayer. They can also be coupled to one or more liposomes or one or more niosomes.
- the peptide (s) according to the invention can be expressed in a recombinant virus, or a recombinant viral vector, or in an attenuated or inactivated virus.
- the peptide (s) according to the invention can be expressed in a recombinant bacterium or in a recombinant bacterial vector.
- the peptide (s) according to the invention can be expressed in an antigen presenting cell.
- Another subject of the invention is a vaccine comprising at least one naked DNA or a naked RNA encoding at least one peptide according to the invention.
- the agent for treating patients infected with HIV comprises at least two compositions, the first composition comprising at least one medicament from the NRTI and / or NNRTI family, and the second composition comprising at least one peptide according to the invention. These compositions are intended for a sequential application, separate or not in time or simultaneous.
- the agent for treating patients infected with HIV comprises at least two compositions, the first composition comprising at least one medicament from the NNRTI family, and the second composition comprising at least one peptide according to the invention.
- Another object of the invention is a method of preventing or treating an infection with the HIV virus.
- This method consists in inducing a specific type T immune response in response to the administration of a vaccine according to the invention.
- the mutation or mutations of the VTH virus are located in the reverse transcriptase enzyme.
- Another subject of the invention is peptide sequences of 8 to 20 amino acids, recognized as epitopic sequences by T cells specific for the peptide sequences corresponding prior to vaccination, introduced to vaccination.
- the epitopic sequences according to the invention are peptide sequences of 8 to 20 contiguous amino acids chosen from the peptide sequences from A to K having at least one Mp mutation.
- these peptide sequences consist of 8 to 10 contiguous amino acids chosen from the peptide sequences from A to K having at least one Mp mutation.
- the epitopic sequences according to the invention consist of 9 contiguous amino acids chosen from the peptide sequences from A to K having at least one Mp mutation.
- the epitopic sequences possessing the stated characteristics can be used for the determination and the quantification of the T cells specific for these epitopic sequences.
- the subject of the invention is also a diagnostic composition for determining the T cells specific for these epitopic sequences, characterized in that it comprises, inter alia, at least one epitopic sequence according to the invention.
- the vaccines obtained according to the methods of the invention can be formulated as pharmaceutical compositions for subcutaneous, intramuscular, intra-dermal or intravenous administration. The techniques for administering this type of vaccine are abundantly described in the literature and are well known to those skilled in the art.
- compositions according to the invention can be sterilized by conventional and known sterilization methods.
- compositions according to the invention can be presented in all the forms usually used in diagnosis.
- compositions according to the invention can in particular contain pharmaceutically acceptable substances such as pH stabilizers, buffering agents or for example sodium acetate, sodium chloride, potassium, calcium, lactate sodium or others in order to be in physiological conditions.
- pharmaceutically acceptable substances such as pH stabilizers, buffering agents or for example sodium acetate, sodium chloride, potassium, calcium, lactate sodium or others in order to be in physiological conditions.
- HIV-specific lines were generated by co-culture of PBMC (peripheral blood mononuclear cells) of patients and of autologous PHA-blasts.
- PBMC peripheral blood mononuclear cells
- PHA phytohemagglutinin
- CTLs lines are cultured for at least 3 weeks in the presence of Interleukin 2 at 20 U / ml, added on the third day of culture and then every 3 days. These lines are tested for their cytotoxic activity after at least 3 weeks of culture against autologous B-EBV lines (B lymphocytes transformed by EBV) serving as targets.
- Interleukin 2 at 20 U / ml
- the target cells are autologous B-EBV lines infected with the various recombinant vaccinia viras expressing the pol gene or fragments of the pol gene of HIV-1, at a multiplicity of infection of 5 PFU (Plaque Forming Unit) / cell , 18h before the CTL test.
- the non-recombinant wild vaccinia virus (Vac-WT) serves as a control.
- the target cells are incubated in a pellet in the presence of Na2 ⁇ Cr ⁇ 4 (specific activity 2 mci / ml), at the concentration of 70 ⁇ ci / xlO ⁇ cells, for 2 h at 37 ° C.
- the CTL responses are considered positive when more than 10% lysis is obtained. specific, this at least 2 successive effector / target ratios.
- RT-1 1-143 and RT-2: 143-293 regions
- Cytotoxic T responses were assessed using a chromium 51 release test.
- the target cells were autologous B-EBV-lines infected with vaccinia viruses expressing different fragments of rt genes (RT-1: 1- 143 and RT-2: 143-293).
- Resistance mutations were detected in proviral DNA using a LiPA HIV-1 RT test (Murex. Diagnostics SA, Châtillon, France). This test allows the simultaneous detection of “wild” type sequences and resistance mutations (41, 69, 70, 74, 184, 214 and 215) induced by nucleoside RT inhibitors (NRTI). From the DNA isolated from PBMCs, an amplification of the rt gene is carried out using biotinylated primers, the biotinylated DNA is then hybridized with specific oligonucleotide probes immobilized in parallel lines on a strip.
- LiPA HIV-1 RT test Murex. Diagnostics SA, Châtillon, France. This test allows the simultaneous detection of “wild” type sequences and resistance mutations (41, 69, 70, 74, 184, 214 and 215) induced by nucleoside RT inhibitors (NRTI). From the DNA isolated from PBMCs, an amplification of the rt gene is carried out using
- an ELISpot-IFN ⁇ test in which the PBMCs were incubated, without prior stimulation, with the peptide of interest was used.
- the 96 wells of a Immobilon p type plate (Millipore, Molsheim, France) are covered for 18 h at 4 ° C with a monoclonal anti-IFN ⁇ (interferon ⁇ ) capture antibody (IgGl B-Bl at 1 ⁇ g / ml Diaclone, Besanarme, France). After 3 washes, the
- PBMCs are added in triplicate at the concentration of 1x10 ⁇ and 5x10 ⁇ cells per well in the presence of 5 ⁇ g / ml of peptide or 0.5 ⁇ g / ml of PHA, used as a positive control or of medium alone used as a negative control.
- the plates are then incubated for 40 h at 37 ° C. in a humid atmosphere at 5% CO 2, then washed, the biotinylated monoclonal anti-IFN ⁇ detection antibody (B-Gl at 0.2 ⁇ g / ml Diaclone,
- Example No. 5 Cutting the sequence B (aa 30-50) into different peptides of length varying between 8 and 21 amino acids.
- the peptide sequences are cut into peptides of 8 to 80 amino acids (aa) involving any part of the sequence covering at least one mutation, this for therapeutic or diagnostic applications.
- Example No. 6 Detection of resistance mutations on pro viral PNA isolated from blood mononuclear cells (CMNS) of patient 201 # 5.
- CMNS blood mononuclear cells
- the resistance mutations were detected in the proviral DNA using a LiPA HIV-1-RT test (see example 3).
- the LiPA test allows the definition of mutated amino acids from time to time within of a given sequence and not that of nucleic acid sequences.
- the method for detecting resistance mutations in DNA is summarized in Figure 1.
- the RT sequence of patient 201 # 5 is as follows:
- the recognition of the mutation 41 (M> L) of RT by the CD8 cells producing IFN-gamma is studied in patient 201 # 5 treated with NRTI.
- the mutation 41 had been detected on the proviral DNA isolated from these same CMNS (see example 6).
- the recognition of wild-type and mutated peptides 33-41 was evaluated by
- the recognition frequency of the mutated 33-41 peptide is 95 SFC / 10 6 CMNS and 3 SFC / 10 6 CMNS for the wild type 33-41 peptide.
- a lipopeptide consists of a palmitic acid of formula C 16 H 32 O 2 or described in the text as C 15 H 3r COOH, of a lysine residue (amino acid basic added to the N-terminus of the peptide) and a peptide whose structure is chosen from the sequences described.
- a lysine residue amino acid basic added to the N-terminus of the peptide
- M2 (aa 39) can be X39 or be mutated into A, K, N, P, M or S;
- M3 (aa 41) can be X41 or be mutated to L; at least one of M2 and M3 representing an amino acid carrying a mutation.
- amino acid 50 which is an isoleucine (I).
- the amino function of the lysine side chain is modified by a palmitic acid and the terminal amino acid C is amidated according to the following reactions: aa30-aa50-NH2 + lysine - »aa30-aa50-NH-CO-Lysine aa30- aa50 -NH-CO-Lysine + COOH-C 15 H 31 CONH2-aàa30-aa50 -NH-CO-Lysine-NH-CO-C 15 H 31
- lysine can be added to the C-terminus of the peptide.
- This structure is then purified and conditioned according to industrial processes meeting the conditions necessary for obtaining clinical batches before use for immunization in humans.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/489,123 US20050074463A1 (en) | 2001-09-14 | 2001-09-14 | Therapeutic vaccination method, mutated peptides of hiv reverse transciptase and their use for vaccination and diagnostic purposes |
JP2003529940A JP2005503418A (ja) | 2001-09-14 | 2001-09-14 | 治療的ワクチン接種法、hiv逆転写酵素の突然変異ペプチドならびにワクチン接種及び診断目的のためのそれらの使用 |
PCT/FR2001/002872 WO2003025166A1 (fr) | 2001-09-14 | 2001-09-14 | Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic |
EP01969902A EP1425391A1 (fr) | 2001-09-14 | 2001-09-14 | Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic |
CA002460377A CA2460377A1 (fr) | 2001-09-14 | 2001-09-14 | Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FR2001/002872 WO2003025166A1 (fr) | 2001-09-14 | 2001-09-14 | Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003025166A1 true WO2003025166A1 (fr) | 2003-03-27 |
Family
ID=8860669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/002872 WO2003025166A1 (fr) | 2001-09-14 | 2001-09-14 | Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050074463A1 (fr) |
EP (1) | EP1425391A1 (fr) |
JP (1) | JP2005503418A (fr) |
CA (1) | CA2460377A1 (fr) |
WO (1) | WO2003025166A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006091798A2 (fr) * | 2005-02-22 | 2006-08-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccins et methodes destines a la prevention et au traitement des virus pharmacoresistants vih-1 et vhb |
US7812052B2 (en) * | 2004-11-02 | 2010-10-12 | Ebewe Pharma Ges.m.b.H. NFG KG | Stable aqueous formulation of a platin derivative |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG163572A1 (en) * | 2005-07-11 | 2010-08-30 | Globeimmune Inc | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
RU2505313C2 (ru) * | 2007-03-19 | 2014-01-27 | Глоубиммьюн, Инк. | Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1135468B1 (fr) * | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Vecteurs viraux et leurs procedes d'elaboration et d'administration |
-
2001
- 2001-09-14 CA CA002460377A patent/CA2460377A1/fr not_active Abandoned
- 2001-09-14 JP JP2003529940A patent/JP2005503418A/ja active Pending
- 2001-09-14 WO PCT/FR2001/002872 patent/WO2003025166A1/fr active Application Filing
- 2001-09-14 EP EP01969902A patent/EP1425391A1/fr not_active Withdrawn
- 2001-09-14 US US10/489,123 patent/US20050074463A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
SAMRI A ET AL: "Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.", JOURNAL OF VIROLOGY. UNITED STATES OCT 2000, vol. 74, no. 19, October 2000 (2000-10-01), pages 9306 - 9312, XP002213583, ISSN: 0022-538X * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7812052B2 (en) * | 2004-11-02 | 2010-10-12 | Ebewe Pharma Ges.m.b.H. NFG KG | Stable aqueous formulation of a platin derivative |
WO2006091798A2 (fr) * | 2005-02-22 | 2006-08-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccins et methodes destines a la prevention et au traitement des virus pharmacoresistants vih-1 et vhb |
WO2006091798A3 (fr) * | 2005-02-22 | 2007-07-12 | Us Gov Health & Human Serv | Vaccins et methodes destines a la prevention et au traitement des virus pharmacoresistants vih-1 et vhb |
US9474793B2 (en) | 2005-02-22 | 2016-10-25 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus |
Also Published As
Publication number | Publication date |
---|---|
CA2460377A1 (fr) | 2003-03-14 |
EP1425391A1 (fr) | 2004-06-09 |
US20050074463A1 (en) | 2005-04-07 |
JP2005503418A (ja) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Takahashi et al. | An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. | |
Daniel et al. | Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene | |
JP3871708B2 (ja) | 抗原的に標識した非感染性レトロウィルス様粒子 | |
US10335482B2 (en) | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer | |
BRPI0714714A2 (pt) | composiÇÕes de polipeptÍdeo de retrovÍrus endàgeno humano e (herv) e seus mÉtodos e usos | |
JP2569185B2 (ja) | 抗hiv応答を喚起する合成抗原 | |
EP1001815A1 (fr) | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules | |
Ahmad | The vertical transmission of human immunodeficiency virus type 1: molecular and biological properties of the virus | |
US5336758A (en) | Peptides stimulating cytotoxic T cells immune to HIV RT | |
EP1425391A1 (fr) | Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic | |
Bachelez et al. | Oligoclonal expansion of HIV-specific cytotoxic CD8 T lymphocytes in the skin of HIV-1-infected patients with cutaneous pseudolymphoma. | |
US5747526A (en) | Anti-HIV /Aids Chemo(C)-, immuno(I)-, or ci-therapy using tur (or related compounds) and/or NVA (or EPV) | |
GARDNER | Vaccination against SIV infection and disease | |
Nardelli et al. | Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide. | |
JP6152944B2 (ja) | 束縛免疫原性組成物およびその用途 | |
EP0783038A1 (fr) | Pseudo-particules virales recombinantes et applications vaccinales et antitumorales | |
JP2010029217A (ja) | Hiv特異的ctlを誘導し得るペプチド及び該ペプチドを含む抗aids予防・治療剤 | |
Wainberg et al. | Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. | |
JP2014512353A (ja) | 抗ウイルス組成物 | |
US9682137B2 (en) | Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties | |
JP2002501369A (ja) | Fivワクチン | |
US20210317192A9 (en) | Hiv-1 specific immunogen compositions and methods of use | |
RU2600162C1 (ru) | Способ лечения и профилактики вич-инфекции типа 1 субтипа а | |
Wang et al. | Pattern of gp120 sequence divergence linked to a lack of clinical progression in human immunodeficiency virus type 1 infection. | |
EP2821082A1 (fr) | Procédé de production d'un lentivirus inactivé, notamment le VIH, vaccin, kit et procédé d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001969902 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2460377 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003529940 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001969902 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10489123 Country of ref document: US |